Alnylam Pharmaceuticals, Inc. (LON:0HD2)
451.70
+1.69 (0.38%)
At close: Oct 3, 2025
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $773.69M USD in the quarter ending June 30, 2025, with 17.26% growth. This brings the company's revenue in the last twelve months to $2.46B, up 5.01% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.
Revenue (ttm)
$2.46B
Revenue Growth
+5.01%
P/S Ratio
24.70
Revenue / Employee
$1.10M
Employees
2,230
Market Cap
44.39B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Alnylam Pharmaceuticals News
- 3 days ago - Alnylam Pharmaceuticals (ALNY) Pulls Ad After FDA Warning - GuruFocus
- 3 days ago - Alnylam yanks Amvuttra TV ad following FDA letter - report - Seeking Alpha
- 4 days ago - Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Nasdaq
- 4 days ago - CGGR, NFLX, ALNY, BAC: ETF Inflow Alert - Nasdaq
- 4 days ago - Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran - Business Wire
- 7 days ago - Alnylam (ALNY): Vutrisiran Shows Promise in Reducing Gastrointestinal Events - GuruFocus
- 7 days ago - New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran - Business Wire
- 9 days ago - $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Benzinga